Aisling Capital Management LP Invests $762,000 in OnKure Therapeutics (NASDAQ:OKUR)

Aisling Capital Management LP bought a new stake in OnKure Therapeutics (NASDAQ:OKUR) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 88,607 shares of the company’s stock, valued at approximately $762,000. OnKure Therapeutics makes up 0.3% of Aisling Capital Management LP’s holdings, making the stock its 14th biggest position. Aisling Capital Management LP owned about 2.65% of OnKure Therapeutics as of its most recent SEC filing.

Separately, Geode Capital Management LLC bought a new position in OnKure Therapeutics during the fourth quarter worth about $659,000. 90.98% of the stock is owned by institutional investors and hedge funds.

OnKure Therapeutics Stock Performance

Shares of NASDAQ OKUR opened at $4.26 on Wednesday. The company has a market capitalization of $57.24 million, a price-to-earnings ratio of -0.35 and a beta of 0.28. The business’s 50 day moving average price is $5.21. OnKure Therapeutics has a 1-year low of $4.11 and a 1-year high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Monday, March 10th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, research analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

OKUR has been the topic of several research analyst reports. Leerink Partners began coverage on OnKure Therapeutics in a research note on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective on the stock. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Oppenheimer cut their price target on OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a report on Tuesday, March 11th. Finally, HC Wainwright decreased their price objective on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday, March 18th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, OnKure Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $32.33.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.